Featured
Luxa Biotechnology Announces Publication in Cell Stem Cell Describing Positive Clinical Results for First-in-Human Clinical Trial for Dry AMD Therapy
press release
Luxa Biotechnology Announces Publication in Cell Stem Cell Describing Positive Clinical Results for First-in-Human Clinical Trial for Dry AMD Therapy
press release
Read more →
press release
Interview with Luxa Biotechnology Leadership: Promising Results of RPESC-RPE-4W for Dry AMD
press release
Interview with Luxa Biotechnology Leadership: Promising Results of RPESC-RPE-4W for Dry AMD
press release
Read more →
press release
Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting
press release
Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting
press release
Read more →
press release
Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference
press release
Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference
press release
Read more →
press release
Luxa's stem cell therapy for dry AMD shows early promise
press release
Luxa's stem cell therapy for dry AMD shows early promise
press release
Read more →
press release
Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration
press release
Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration
press release
Read more →
press release
Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer
press release
Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer
press release
Read more →
press release
Luxa Biotechnology Receives $4 Million Grant for Clinical Trial of Dry AMD Treatment
press release
Luxa Biotechnology Receives $4 Million Grant for Clinical Trial of Dry AMD Treatment
press release
Read more →
press release
Luxa Biotechnology announces paper on 'Identification of Biomarkers for Diversity and Transplantation Efficacy of Retinal Pigment Epithelial Cells' by Dr. Sally Temple.
press release
Luxa Biotechnology announces paper on 'Identification of Biomarkers for Diversity and Transplantation Efficacy of Retinal Pigment Epithelial Cells' by Dr. Sally Temple.
press release
Read more →
press release
Luxa Biotechnology to Provide Update on Clinical Trial of Retinal Pigmented Epithelium Stem Cell (RPESC) Technology for Treatment of Dry Age-Related Macular Degeneration in Panel Session at ARVO
press release
Luxa Biotechnology to Provide Update on Clinical Trial of Retinal Pigmented Epithelium Stem Cell (RPESC) Technology for Treatment of Dry Age-Related Macular Degeneration in Panel Session at ARVO
press release
Read more →
press release